Post-Rebif, Merck KGaA Keeps Faith With MS Therapies
Executive Summary
CEO Stefan Oschmann is sticking to his previous forecast of annual peak sales of €500-700m for Mavenclad, excluding the US, and Merck has high hopes for another MS treatment, the BTK inhibitor evobrutinib, following promising Phase IIb data.
You may also be interested in...
Merck KGaA Rules Out Major M&A, Says MS Pill Mavenclad Will Be Major Earner
The German group has been laying out its future plans to investors, which include reducing debt and a strong revenue stream from its Pfizer-partnered checkpoint inhibitor Bavencio.
Merck KGaA's MS Drug Mavenclad May Defy Doubters
The German group's oral treatment is late coming to the market but a key opinion leader believes that it will change the way multiple sclerosis is treated.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.